Our voyage of discovery involves coupled Artificial Intelligence and Mass Spectrometry to speed up identifying unique molecules that can trigger biological switches within the human body.
Affinity Selection – Mass Spectrometry
Our NIH-approved proprietary platform rapidly and efficiently scans natural compounds to visualize their mode of action against various diseases and determine their potential therapeutic use.
Artificial Intelligence & Machine Learning
Using data from our proprietary AS-MS platform, our machine learning platform yields – More compounds with therapeutic use; and Greater certainty and regulatory confidence while potentially reducing standard Preclinical and Clinical Trial steps.